GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Meta] the SURMOUNT rule is doing its job and people should stop complaining — 69 comments in the full submission. View in context.
3.9k
c/tirzepatide·submitted 2 years ago by u/hugo_bergstrom

[Meta] the SURMOUNT rule is doing its job and people should stop complaining

Resultsbranch of 6 comments

the SURMOUNT rule is doing its job and people should stop complaining. Nothing about this affects the ranking maths, before anyone asks. Switching from semaglutide, since three people asked in this thread alone. There is no published dose equivalence between the two. The conversion tables that circulate are…

Read the full submission and all 69 comments →

This branch

6 comments, started 2 years ago
u/customs_seizure_sid296 points·2 years ago

I would separate the two claims. That the GIP arm exists is uncontroversial; that it explains your early fullness pattern is a guess.

replysharereportpermalink
[removed]208 points·2 years ago

[removed by moderator]

replysharereportpermalink
u/search_before_post240 points·2 years ago

2.5 is the starter dose and it is not meant to be the dose that works

replysharereportpermalink
u/laila_wikstrom188 points·2 years ago

The 21% figure is a 72-week mean on the highest arm. Quoting it as what someone should expect by week 31 is not a fair reading.

replysharereportpermalink
u/piotr_nascimento42 points·2 years ago

week 2 is early to draw any conclusion at all

replysharereportpermalink
u/amara_halonen418 points·2 years ago

Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.

replysharereportpermalink

← back to the whole thread

About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/tirzepatide
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/titration_marshalu/incretin_ivyu/quiet_moderatoru/dexa_twice_yearly
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →